Technology Innovation Institute Introduces World’s Most Powerful Open LLM: Falcon 180B
6.9.2023 16:20:00 EEST | Business Wire | Press release
The Technology Innovation Institute (TII) in the United Arab Emirates (UAE) is pushing the boundaries of generative AI once again with the launch of Falcon 180B, an advanced iteration of its flagship large language model (LLM). This groundbreaking release strengthens the UAE's dominance in AI, offering Falcon 180B as an open access model for research and commercial purposes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230906583274/en/
Falcon 180B Benchmarks (Photo: AETOSWire)
Following the remarkable success of Falcon 40B, an open source AI model that swiftly ascended to the top of the Hugging Face Leaderboard for LLMs in May 2023, TII, the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC) continues to lead the charge in generative AI. Falcon 40B marked one of the first instances of open source models for both researchers and commercial users, and it was considered a pioneering leap in the field.
H.E. Faisal Al Bannai, Secretary General of the Advanced Technology Research Council, emphasized the positive impact of Falcon on the AI landscape and said: “We envision a future where the transformative power of AI is within everyone's reach. We are committed to democratizing access to advanced AI, as our privacy and the potential impact of AI on humanity should not be controlled by a select few. While we may not have all the answers, our resolve remains unwavering: to collaborate and contribute to the open source community, ensuring that the benefits of AI are shared by all.”
With a staggering 180 billion parameters and trained on 3.5 trillion tokens, Falcon 180B soars to the top of the Hugging Face Leaderboard for pretrained LLMs. It outperforms notable competitors like Meta’s LLaMA 2 in various benchmarks, including reasoning, coding, proficiency, and knowledge tests.
Among the best closed source LLMs, Falcon 180B ranks just behind OpenAI's latest GPT 4 and is on par with the performance of Google's PaLM 2 Large, the model powering Bard – despite being half the size of the model. The licensing framework for the model is established on ‘Falcon 180B TII License’, which is based upon Apache 2.0.
Dr. Ebtesam Almazrouei, Executive Director and Acting Chief Researcher of the AI Cross-Center Unit at TII, said: "The launch of Falcon 180B exemplifies our dedication to advancing the frontiers of AI, and we are thrilled to share its limitless potential with the world. Falcon 180B heralds a new era of generative AI, where the potential of scientific advancement is made available through open access to fuel the innovations of tomorrow. As we delve into frontiers of science and technology, our vision extends far beyond innovation; it's about nurturing a profound connection to address global challenges through collaborative breakthroughs.”
With over 12 million developers adopting and deploying the first release of Falcon, this significant upgrade is poised to become the premier model for various domains, from chatbots to code generation, and beyond.
Falcon 180B is compatible with the following major languages: English, German, Spanish, and French, with limited capabilities in Italian, Portuguese, Polish, Dutch, Romanian, Czech, and Swedish.
For more information, please visit FalconLLM.tii.ae
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230906583274/en/
Contact information
Jennifer Dewan, Senior Director of Communications
jennifer.dewan@tii.ae.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom